2014 Press Releases
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004
DateTitle 
04/15/14WuXi PharmaTech Files 2013 Annual Report on Form 20-F
SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2013, with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to it... 
Printer Friendly Version
04/15/14WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang Joins Company as EVP and Chief Operating Officer; Edward Hu Named Chief Investment Officer and Remains Chief Financial Officer SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Dr. Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will ... 
Printer Friendly Version
04/07/14WuXi PharmaTech Receives Honorable Mention at 2014 ISPE Facility of the Year Awards
... 
Printer Friendly Version
04/01/14WuXi PharmaTech Corporate Venture Fund Invests in TruTag Security Platform for Drug Safety
SHANGHAI and HONOLULU, April 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, and TruTag Technologies, Inc., developer of the leading edible, covert security platform to address the global product counterfeiting challenge, today announced that WuXi Corporate Venture Fund has made an investment in TruTag. In addition, WuXi and TruTag will explore co... 
Printer Friendly Version
03/11/14WuXi PharmaTech and Pacific Biomarkers Announce Collaboration
SHANGHAI and SEATTLE, March 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle, today announced a biomarker collaboration.  In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clin... 
Printer Friendly Version
03/10/14WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
SAN DIEGO and SHANGHAI, March 10, 2014 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome... 
Printer Friendly Version
03/05/14WuXi PharmaTech Announced Fourth-Quarter and Full-Year 2013 Results
... 
Printer Friendly Version
02/26/14WuXi PharmaTech Announces Appointment of Dr. Hua Mu to Head Product Development Service and Partnership Business Unit
SHANGHAI, Feb. 26, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that Dr. Hua Mu has joined WuXi as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit, reporting to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  Dr. Mu has over 18 years of clinical research and... 
Printer Friendly Version
02/10/14WuXi PharmaTech Schedules Fourth-Quarter and Full-Year 2013 Earnings Release
SHANGHAI, Feb. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter and full year of 2013 after the New York Stock Exchange closes on Wednesday, March 5, 2014 (which will be Thursday morning, March 6, 2014 Shanghai time). The earnings release will be available on the inves... 
Printer Friendly Version
01/10/14WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
SHANGHAI, Jan. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in China and the United States, today announced that it updated its 2013 financial guidance. The company expects to achieve total revenues for full-year 2013 of approximately $578 million. The company expects diluted EPS for full-year 2013 to slightly exceed the top end of its previous guidance of $1.51-$1.55 (G... 
Printer Friendly Version